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Abstract
Background: Crimean-Congo hemorrhagic fever (CCHF) is an endemic zoonosis in Kastamonu, Turkey. Clinical and laborato-
ry findings may not be specific in the early phase of  the disease, hence bringing a challenge to the clinician.
Objective: We aimed to distinguish CCHF cases among all suspected cases by comparing them with non-CCHF cases with 
respect to characteristics during admission.
Methods: Cases with a presumptive diagnosis of  CCHF at a secondary care hospital in Kastamonu in between 2014-2017 were 
evaluated, retrospectively. CCHF and non-CCHF cases were compared with respect to their clinical, laboratory and epidemio-
logical characteristics during admission.
Results: Among 76 suspected patients,  CCHF was found in 46.1% of  them. Four-year fatality rate was 9.6% in CCHF cases. 
The frequency of  headache, nausea/vomiting, leukopenia, thrombocytopenia less than 50x109/L, AST-ALT and LDH elevation, 
tick bites and contact with blood or body fluids of  animals in CCHF cases were significantly higher than in non-CCHF cases 
(p<0.05). 
Conclusion: Headache and nausea/vomiting accompanied with leukopenia, thrombocytopenia less than 50x109/L, AST-ALT 
and LDH elevations raise the possibility of  CCHF in endemic regions especially when there is a history of  tick bite and contact 
with blood or body fluids of  animals. 
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Introduction
Crimean-Congo hemorrhagic fever (CCHF) is a viral 
zoonotic infection caused by CCHF virus (CCHFV), a 
member of  Bunyaviridae family. It is transmitted to humans 
through Hyalomma tick bites and blood or body fluids 
of  infected animals or individuals. The clinical spectrum 
is wide from a self-limited disease to serious fatal infec-
tion. The fatality rate was reported to be 10–40%1-7. The 
disease was reported in the Crimea in 1944 for the first 
time2. Thereafter, it has been reported from many regions 
of  Africa, Asia, Eastern Europe, the Balkans and the 
Middle East6-9. In Turkey, the first CCHF case was seen 
in the Kelkit Valley region in 2002. CCHF is an endem-
ic zoonosis in Turkey occurring every year in spring and 
summer months. The number of  annually reported cases 
in Turkey is nearly 10001-7. Compared with the countries 
that report CCHF cases, the highest number of  CCHF 
cases has been reported annually from Turkey. Most of  
the cases in Turkey were from 15 cities in Kelkit Valley re-
gion and its environs including Kastamonu Province4,9-14. 
The fatality rate of  CCHF in Turkey changes between 3% 
and 9%15-17.
 
There are a limited number of  studies investigating char-
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acteristics of  patients with a presumptive diagnosis of  
CCHF during admission1,16-20. In this study, we aimed to 
reveal characteristics of  CCHF suspected cases admitted 
to a secondary care hospital in Kastamonu, Turkey be-
tween 2014-2017. It was also investigated whether there 
is a difference between CCHF cases and non-CCHF cas-
es in terms of  clinical, laboratory and epidemiological 
characteristics. 
Methods
Patients with a presumptive diagnosis of  CCHF ad-
mitted to inpatient clinic in Kastamonu State Hospital 
(Kastamonu Province, Turkey) between 2014-2017 were 
enrolled in this study. A presumptive diagnosis of  CCHF 
was made if  cases met minimum two of  the five follow-
ing criteria: sudden onset high fever, headache, weakness, 
nausea/vomiting and diarrhea plus one of  the following 
two criteria: thrombocytopenia (platelet count of  <150 
x 109/L), leukopenia (white blood cell count of  <4 x 
109/L), and also one of  the below criteria: history of  tick 
bite, close contact with animals, living in or travelling to 
rural areas, contact with people with similar symptoms in 
the past two weeks. 
 
Serum samples of  the cases were obtained upon admis-
sion and were sent to the Public Health Institution of  
Turkey, National Virology Reference Laboratory to in-
vestigate CCHF IgM antibodies by ELISA and CCHFV 
RNA by PCR. ELISA was not performed on serum sam-
ples if  positive viral RNA was detected by PCR. 
 
When CCHFV RNA or CCHF IgM was detected posi-
tive,  CCHF diagnosis was confirmed. If  both viral RNA 
and IgM antibody were negative, CCHF diagnosis was 
excluded. Cases with a history of  suspected CCHF in the 
past four months were excluded from the study because 
serum CCHF IgM antibodies detected by ELISA can re-
main positive during four months2,4,6,7. The incubation 
period was defined as the interval between tick contact 
and appearance of  symptoms. Cases diagnosed with han-
tavirus infection were excluded from the study, since han-
tavirus infection and CCHF are both viral hemorrhagic 
fevers that have similar clinical and laboratory properties. 
CCHF cases were evaluated retrospectively with respect 
to their clinical and laboratory values during admission to 
the hospital and epidemiological data within two weeks, 
and these characteristics of  CCHF cases were compared 
with non-CCHF cases. 
 
Statistical analysis was performed using SPSS version 15.0 
(SPSS Inc., USA). Descriptive statistics (median, mini-
mum and maximum value, mean and standard deviation, 
count and percentage) were used to summarize the re-
sults. Nominal variables were compared with χ2 test and 
Fisher’s exact test. Continuous variables were compared 
with Student’s t test and Mann Whitney U test. A p value 
of  less than 0.05 was accepted as statistically significant.
 
Results
In total,  79 cases with suspected CCHF were followed up 
as inpatients in our hospital between 2014-2017. Three 
cases with hantavirus infection were excluded from the 
study. So, the remaining 76 cases were subjected to our 
study. 
 
Two had a positive IgM by ELISA and 29 cases had a 
positive PCR for CCHFV RNA. So, a total of  31 cases 
(40.7%) were diagnosed with definitive CCHF. The re-
maining 45 cases (59.3%) were found negative by both 
tests, also they did not get a specific infectious disease 
diagnosis. So, they were considered as non-CCHF cases. 
61.3% (19) of  the CCHF cases were female, while 38.7% 
(12) were male. However, 48.9% (22) and 51.1% (23) of  
the non-CCHF cases were female and male, respective-
ly. The mean age of  CCHF cases and non-CCHF cases 
was 52.8±16.1 and 54.4±19.1, respectively. There were 
no statistically significant differences between the two 
groups regarding gender and age (p> 0.05). 20 cases from 
the CCHF group were referred to a tertiary care hospi-
tal, because their thrombocyte levels decreased below 
50x109/L during follow-up. Three of  the referred CCHF 
cases deceased while the other 17 cases survived. Cases 
who deceased were all female and they were 39,66 and 79 
years old. They had no underlying diseases and mortali-
ty was due to multi-organ failure. Hence, the fatality rate 
was 9.6% (3/31) in the CCHF group. 
Monthly distribution of  the CCHF and non-CCHF cases 
was shown in Figure 1. It was seen that the earliest case 
was detected in February and the highest number of  cas-
es was admitted in June.  Annual distribution of  CCHF 
and non-CCHF cases was shown in Figure 2. It was seen 
that the number CCHF suspected admissions and con-
firmed cases had gradually decreased from 2014 to 2017. 
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Figure 1: Monthly distribution of CCHF and non-CCHF cases during a four-year period. 
 
 
Figure 2: Annual distribution of CCHF and non-CCHF cases between 2014-2017. 
Clinical symptoms of  the cases during admission were 
summarized in Table 1. The most common physical 
finding during admission was fever, which was present 
in 61.3% (19) of  CCHF and 66.7% (30) of  non-CCHF 
cases. In the CCHF group, three (9.7%) cases had macu-
lopapular rash, one (3.2%) had altered level of  conscious-
ness, hypotension and tachycardia and another one (3.2%) 
had petechiae and hypotension during admission. In the 
non-CCHF group, three (6.7%) cases had hemorrhagic 
findings, three (6.7%) had hypotension and tachycardia, 
two (4.4%) had maculopapular rash, and one (2.2%) had 
ecchymosis and altered level of  consciousness. There 
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was no statistically significant difference between the two 
groups in terms of  physical findings during admission 
Table 1: Clinical symptoms of the cases with a presumptive diagnosis of 
Crimean-Congo hemorrhagic fever during admission 
 
  CCHF cases 
(31) 
Non-CCHF cases(45) p value 
Clinical symptoms % (n) % (n)   
Fatigue 100 (31) 100 (45) p>0.05 
Widespread myalgia 100 (31) 91.1 (41) p>0.05* 
Fever 96.8 (30) 82.2 (37) p>0.05* 
Headache 96.8 (30) 75.6 (34) p<0.05* 
Nausea and vomiting 83.9 (26) 51.1 (23) p<0.05 
Abdominal pain 41.9 (13) 28.9 (13) p>0.05 
Diarrhea 38.7 (12) 20 (9) p>0.05 
Maculopapular rash 9.7 (3) 4.4 (2) p>0.05* 
Altered consciousness 3.2 (1) 13.3 (6) p>0.05* 
Bleeding 9.7 (3) 6.7 (3) p>0.05* 
* Fisher’s exact test 
  
Table 2: Laboratory findings of cases with a presumptive diagnosis of 
Crimean-Congo hemorrhagic fever during admission 
 
  CCHF cases (31) Non-CCHF 
cases(45) 
p value  
Laboratory findings % (n) % (n)   
Thrombocytopenia 93.5 (29) 77.8 (35) p>0.05* 
Platelet count:       
101-150x109/L 32.3(10) 31.1(24) p>0.05 
51-100x109/L 25.8 (8) 46.6 (21) p>0.05 
<50x109/L 35.5 (11) 2.2 (1) p<0.05* 
Leukopenia 93.5 (29) 57.8 (26) p<0.05 
AST-ALT elevation 67.7 (21) 42.2 (19) p<0.05 
LDH elevation 87.1 (27) 55.6 (25) p<0.05 
CK elevation 51.6 (16) 31.1 (14) p>0.05 
Anemia 9.7 (3) 15.6 (7) p>0.05* 
INR elevation 32.3 (10) 15.6 (7) p>0.05 
* Fisher’s exact test 
  
(p> 0.05). Laboratory findings of  the cases during admis-
sion are summarized in Table 2.
When the cases were evaluated according to their occupa-
tions, most of  them were farming and animal husbandry 
with 66.7% (16) and 71% (22) in the CCHF and the non-
CCHF groups, respectively. There was no occupational 
risk in the remaining cases. Epidemiological data of  the 
cases within the last two weeks were summarized in Table 
3. The mean incubation period of  cases with tick expo-
sure was 3.8 ± 2.7 days in the CCHF group. The median 
day of  illness on which patients were admitted was 2.0 (0-
6) and 1.0 (0-7) days in CCHF and non-CCHF patients, 
respectively and the difference was not statistically signif-
icant (p> 0.05). 
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Discussion
In this study, we found that the frequency of  head-
ache, nausea/vomiting, leukopenia, thrombocytopenia 
less than 50x109/L, AST-ALT and LDH elevation, tick 
bites and contact with blood or body fluids of  animals 
in CCHF cases were significantly higher than non-CCHF 
cases.
CCHFV may be transmitted through the bite of  an in-
fected tick or by exposure to blood or body fluids of  a 
viremic animal or human2,3,6,7. Tick bites and animal hus-
bandry are well-known risk factors for seropositivity. 
Accordingly, history of  tick bite and animal husbandry 
was identified in most CCHF cases in Turkey. Seroprev-
alence was reported as 10% in persons with a history of  
tick bite. However, seroprevalence was reported higher 
in endemic regions of  Turkey (10–19.6%). Seropositivity 
in humans with a history of  farming, animal husbandry, 
contact with animals and contact with ticks was reported 
quite high:  80%, 70%, 76% and 70%,  respectively4,5,21-25. 
Contact with animals was more commonly reported in 
CCHF cases than non-CCHF cases, but, a history of  tick 
bite was similar between the two groups in Bolu,Turkey17. 
Similar to a previous study conducted in our hospital19, 
we found that the frequency of  tick bites was significantly 
higher in CCHF cases than non-CCHF cases (p<0.05). 
Other endemic tick-borne diseases in Kastamonu are tu-
laremia and rickettsiosis, however their clinical presenta-
tions are greatly different from CCHF. 
 
CCHF cases are frequently seen between April and Sep-
tember, with a peak incidence in June and July2,3,6,7. The 
majority of  CCHF cases occurs during May, June and 
July4. Consistently, most CCHF cases in our study was 
seen in June.
 
The number of  male and female CCHF cases was found 
similar in Turkey. Individuals living in rural area and 
working in farming and animal husbandry are under risk 
for CCHF. Consistently, most CCHF cases are farmers 
and animal husbanders.  Housewives in rural areas par-
ticipate actively in farming and animal husbandry in Tur-
key19,21-28. No housewives were present in our study, since 
housewives generally live in rural areas and actively work 
in farming or animal husbandry in Kastamonu, Turkey.19
 
In Turkey, the proportion of  health care staff  with CCHF 
among the whole cases between 2004-2007 was found 
0.4% and seroprevalence among healthcare staff  in en-
demic areas was found 2%4,26.  In our study, there was 
no healthcare staff  diagnosed with CCHF. The propor-
tion of  CCHF cases among all suspected cases was found 
40.7% in our study. No statistically significant difference 
was found between the two groups in terms of  gender 
(p>0.05).
 
The most widespread symptoms in CCHF cases are fe-
ver, headache, myalgia, nausea, vomiting, abdominal pain, 
diarrhea and bleeding,  respectively4,6,7. In some previous 
studies, fever, bleeding, vomiting, headache and diar-
rhea were reported more frequently in CCHF cases than 
non-CCHF cases17,18. In our study, headache and nau-
sea/vomiting were reported more frequently in CCHF 
Table 3: Epidemiological data of cases with a presumptive diagnosis 
of Crimean-Congo hemorrhagic fever in the last two weeks 
 





Epidemiological data % (n) % (n)   
Living in rural area 100 (31) 91.1 (41) p>0.05* 
Animal contact 71 (22) 53.4 (24) p>0.05 
Tick bite 74.2 (23) 44.4 (20) p<0.05 
Contact with blood or 
body fluids of animals 
54.8 (17) 28.9 (13) p<0.05 
Travelling to rural area 22.6 (7) 11.1 (5) p>0.05* 
Contact with CCHF 
cases 
0 (0) 4.4 (2) p>0.05* 
 * Fisher’s exact test 
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cases compared with non-CCHF cases (p<0.05). There 
were no significant differences between the two groups 
in terms of  clinical findings during admission (p>0.05). 
In suspected cases, headache and nausea/vomiting may 
help to differentiate CCHF cases from non-CCHF cas-
es. The number of  patients with hemorrhagic findings 
among CCHF and non-CCHF patients during admission 
was three in each group and the frequency was 9.7% and 
6.7%, respectively.  Contrary to expectations, there is no 
statistically significant difference in terms of  hemorrhag-
ic findings between the groups (p>0.05). This may be 
because patients were admitted in the initial period of  
CCHF. In our study, the median day of  illness on which 
CCHF cases applied to hospital was 2.0 days. Except our 
hospital, there is another private hospital in Kastamonu 
province that serves CCHF suspected cases. Cases with 
hemorrhagic findings might have been admitted to oth-
er hospitals/centers/departments and perhaps they were 
misdiagnosed in other medical departments.
 
Leukopenia, thrombocytopenia, raised AST-ALT, CK 
and LDH levels are the most widespread laboratory ab-
normalities in CCHF cases1,4,6,7. In some previous studies, 
thrombocytopenia, elevated AST-ALT and LDH levels 
were reported more frequently among CCHF cases than 
non-CCHF cases17,18. In our study; leukopenia, AST-ALT 
and LDH elevations were more frequently seen in CCHF 
cases (p<0.05),but, other laboratory findings during ad-
mission were found similar between the two groups 
(p>0.05). Thrombocytopenia independent from quan-
titative value was not statistically different between the 
two groups (p>0.05), however thrombocyte count less 
than 50x109/L was more frequently seen in CCHF cas-
es (p<0.05).  So, leukopenia, thrombocytopenia less than 
50x109/L), AST-ALT and LDH elevations may help to 
distinguish CCHF cases from non-CCHF cases.
 
The fatality rate of  CCHF is about 10–40%1. The mean 
fatality rate for Turkey was nearly 5% between 2002-
2007. The fatality rate was determined as 8.8% between 
2006-2012 in Bolu Province, 250 km distant in the West 
of  Kastamonu Province in our country17. In our hospital, 
342 CCHF cases were diagnosed between 2005-2010 and 
the fatality rate was reported to be 2.9%15. However, 19 
CCHF cases were diagnosed in our hospital in 2013 and 
the fatality rate was determined as 5.3%19. In our study, 
31 cases were diagnosed with CCHF in 2014-2017 and 
the fatality rate was 9.6%. This fatality rate was consistent 
with the classical literature and similar to the aforemen-
tioned study conducted in Bolu, but higher than other 
studies conducted in Turkey. This may be due to the fact 
that milder cases were less diagnosed, since most outpa-
tients were not tested for CCHF unless their clinical and 
laboratory status exacerbated. Another reason may be 
that more severe patients were admitted to our hospital 
compared to the other hospital in Kastamonu. The fa-
tality differences among studies in different regions may 
be associated with the evolution of  the virus due to the 
climate changes in the course of  time. The number of  
patients admitted with a presumptive diagnosis of  CCHF 
in 2014-2017 had gradually decreased. This may be ex-
plained by the climate changes and changes in the route 
of  migratory birds29,30.
 
The efficacy of  ribavirin in CCHF treatment is still con-
troversial. Although many papers advocated a therapeutic 
benefit related to ribavirin use, the quality of  the evidence 
is low. CCHF treatment is generally based on supportive 
treatment6,7,31,32. In our study, all cases were managed with 
supportive treatment, none of  them received ribavirin 
treatment.
 
Before any conclusion, we should declare study limita-
tions. First, this was a retrospectively single center study 
with a small number of  patients. Second, the study evalu-
ates characteristics of  patients during admission, the pa-
tients could not be evaluated during the course of  the dis-
ease until the patient outcome.  Despite these limitations, 
all patients admitted to our inpatient clinic with CCHF-
like presentation during 2014-2017 were subjected to this 
study. The number of  studies evaluating cases with a pre-
sumptive diagnosis of  CCHF is rather limited1,16-20. Thus, 
more comprehensive studies including large number of  
patients are required. 
CCHF still saves its significance in Kastamonu region of  
Turkey. According to studies from Turkey, fatality rate 
ranges between 5%  and 10%. Although the number of  
annual suspected cases in Kastamonu tended to decrease 
between 2014-2017, the fatality rate in a four-year period 
was found 9.6% in this study similar to other endemic 
countries1-7,15-17. At first visit,  clinical presentation,  phys-
ical and laboratory findings may not be specific in CCHF 
especially in the initial period of  the disease2,3,5-7. In en-
demic regions, clinicians should consider the possibility 
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of  other diseases in cases with CCHF-like presentation 
and distinguish the clinical, laboratory and epidemiologi-
cal features of  CCHF cases during admission.
Conclusion
According to the results of  our study, clinical symptoms 
like headache and nausea/vomiting accompanied with the 
laboratory findings like leukopenia, thrombocyte count 
less than 50x109/L, AST-ALT and LDH elevations raise 
the possibility of  CCHF in endemic regions especially 
when there is a history of  tick bite and contact with blood 
or body fluids of  animals. Clinicians should be more care-
ful in the management of  such cases in order to prevent 
undesired outcomes.
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